Obermatt
See Similar Stocks →

Monte Rosa Therapeutics

NSQ:GLUE · US61225M1027
BiotechnologySmall

360

13
Profit price61
Cash yield1
Price/Sales52
Price/Book44
Return on Capital56
Cash Return on Capital63
Return on Equity65
Profit margins28
Accruals20
Owner Earnings Margin32
Sales growth15
Profit Growth40
Long-Term EPS Growth23
Reinvestment39
Price momentum88
Debt load50
Refinancing27
Debt Payback1
Liquidity5
Analyst ratings56
Opinion Changes50
Price Target Upside58
Market mood25
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Monte Rosa Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2019
Employees180
Websitemonterosatx.com
ISINUS61225M1027
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Machine LearningInflammationCardiovascularGeneticsArtificial IntelligenceImmunologyNeurologyOncology

Description

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. The company has developed a proprietary and industry leading discovery engine, called QuEEN (a…

Analysis

Middle-of-the-road

Monte Rosa Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
36
2026

All-time high

36

Jun 2026

All-time low

30

Mar 2026

Average rank

33

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
—
—
—
Price/Earnings
73
—
—
—
Price/Book
44
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
78
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Monte Rosa Therapeutics with its peers
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nuvectis Pharma
NAQ:NVCT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Praxis Precision Medicines
NSQ:PRAX
37
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →